ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1608

Lack of Early Change in Disease Activity Score Predicts the Likelihood of Achieving Low Disease Activity at Month 6: Tofacitinib Monotherapy Versus Methotrexate in Methotrexate-Naive Patients with Rheumatoid Arthritis

Edward Keystone1, Ronald F van Vollenhoven2, Bethanie Wilkinson3, Lara Fallon4, Lie-Ju Hwang5, Douglass Chapman5, Ryan DeMasi5 and Eun Bong Lee6, 1Mount Sinai Hospital, Toronto, ON, Canada, 2Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, 3Pfizer Inc, Groton, CT, 4Pfizer Canada, Montreal, QC, Canada, 5Pfizer Inc, New York, NY, 6Seoul National University, Seoul, Korea, Republic of

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Disease Activity, rheumatoid arthritis (RA) and tofacitinib

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Monday, November 14, 2016

Session Title: Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Tofacitinib is an oral JAK inhibitor for the treatment of rheumatoid arthritis (RA). Treatment guidelines recommend targeting remission or low disease activity (LDA), herein defined as Disease Activity Scores ≤3.2 based on 28 joint counts (DAS28≤3.2) and adjusting therapy after 3–6 months1 (Mos). Predicting the likelihood of clinical response may help inform early treatment decisions. The aim of this study was to understand the relationship between timing and magnitude of early changes in DAS28, erythrocyte sedimentation rate (DAS28-4[ESR]) and the likelihood of achieving LDA at Mo 6 in RA patients (pts) naïve to methotrexate (MTX).

Methods: In a Phase 3 study (ORAL Start; NCT01039688), MTX-naïve RA pts were randomized 2:2:1 to the following monotherapies: tofacitinib 5 mg twice daily (BID), tofacitinib 10 mg BID or MTX. Conditional probabilities of pts achieving LDA at Mo 6 were calculated, given failure to achieve DAS28-4(ESR) improvement from baseline (range ≥0.3 to 1.8) at Mo 1 or 3. One-year data with non-responder imputation for missing values was used.

Results: 948 pts received treatment; tofacitinib 5 mg BID (n=370), tofacitinib 10 mg BID (n=394) or MTX (n=184); results previously reported.2 In this post-hoc analysis, of those patients who failed to achieve DAS28-4(ESR) improvement from baseline ≥1.2 at Mo 3, 6.8% for tofacitinib 5 mg BID, 11.3% for tofacitinib 10 mg BID, and 6.2% for MTX achieved LDA at Mo 6 (Table). A minority of pts (74/353 [20.9%]) receiving tofacitinib 5 mg BID failed to achieve DAS28-4(ESR) improvement ≥1.2 from baseline at Mo 3, while a greater proportion failed for MTX (65/171 [38.0%]). Failure to achieve DAS28-4(ESR) improvement from baseline at Mo 3 (range ≥0.30–1.8) for tofacitinib 5 mg BID and MTX was associated with a low probability (≤10%) of achieving LDA at Mo 6. For tofacitinib 5 mg BID, failure to achieve lower thresholds of DAS28-4(ESR) improvement (range ≥0.3 to 0.9) at Mo 1 was associated with lower probability of LDA at Mo 6 than higher DAS28-4(ESR) thresholds (≥1.2–1.8) (Table).

Conclusion: Failure to achieve DAS28-4(ESR) improvement ≥1.2 from baseline at Mo 3 was associated with a low probability of achieving LDA at Mo 6 (≤6.8%) for tofacitinib 5 mg BID and MTX. For the minority of MTX-naïve RA pts treated with tofacitinib 5 mg BID or MTX who failed to achieve a minimal clinical response (DAS28-4[ESR] improvement ≥1.2) by Mo 3, another treatment option can be considered at Mo 3, as there is a low probability of reaching LDA at Mo 6. References:  1. Smolen J et al. Ann Rheum Dis 2016;75(1):3-15. 2. Lee EB et al. N Engl J Med 2014;370:2377-2386.


Disclosure: E. Keystone, Pfizer Inc, Eli-Lilly, Amgen, AbbVie, BMS, Roche, 2,Pfizer Inc, Eli-Lilly, Amgen, AbbVie, BMS, Roche, 5; R. F. van Vollenhoven, Pfizer Inc, 2,Pfizer Inc, 5; B. Wilkinson, Pfizer Inc, 1,Pfizer Inc, 3; L. Fallon, Pfizer Inc, 1,Pfizer Inc, 3; L. J. Hwang, Pfizer Inc, 1,Pfizer Inc, 3; D. Chapman, Pfizer Inc, 1,Pfizer Inc, 3; R. DeMasi, Pfizer Inc, 1,Pfizer Inc, 3; E. B. Lee, Pfizer Inc, 5.

To cite this abstract in AMA style:

Keystone E, van Vollenhoven RF, Wilkinson B, Fallon L, Hwang LJ, Chapman D, DeMasi R, Lee EB. Lack of Early Change in Disease Activity Score Predicts the Likelihood of Achieving Low Disease Activity at Month 6: Tofacitinib Monotherapy Versus Methotrexate in Methotrexate-Naive Patients with Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/lack-of-early-change-in-disease-activity-score-predicts-the-likelihood-of-achieving-low-disease-activity-at-month-6-tofacitinib-monotherapy-versus-methotrexate-in-methotrexate-naive-patients-with-rhe/. Accessed January 22, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/lack-of-early-change-in-disease-activity-score-predicts-the-likelihood-of-achieving-low-disease-activity-at-month-6-tofacitinib-monotherapy-versus-methotrexate-in-methotrexate-naive-patients-with-rhe/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.